<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0948441" disease_type="Disease or Syndrome" abbrv="VOD">Veno-occlusive disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e>) of the liver is a clinical syndrome characterized by <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo>, painful <z:hpo ids='HP_0002240'>hepatomegaly</z:hpo>, and fluid retention </plain></SENT>
<SENT sid="1" pm="."><plain>In the bone marrow transplantation (BMT) setting, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e> is caused by dose-intensive chemotherapy and/or radiotherapy used to prepare patients for transplant </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e> occurs in up to 50% of the patients who undergo BMT and is usually associated with a high mortality rate </plain></SENT>
<SENT sid="3" pm="."><plain>Until recently, there was no proven effective medical therapy for this condition once it was clinically apparent </plain></SENT>
<SENT sid="4" pm="."><plain>We report here on the frequency and treatment result of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e> with rt-PA in our allogeneic BMT patients </plain></SENT>
<SENT sid="5" pm="."><plain>Eight patients (median age 28.5 years) underwent allogeneic BMT from December, 1993 to June, 1995 in Asan Medical Center </plain></SENT>
<SENT sid="6" pm="."><plain>Six <z:hpo ids='HP_0001909'>leukemia</z:hpo> patients were prepared for BMT with <z:chebi fb="0" ids="28901">busulfan</z:chebi> and cyclophosphmide, while two <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> patients received <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> and antithymocyte globulin </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e> was defined as having two of the following features before day 20 posttransplant: <z:hpo ids='HP_0000952'>jaundice</z:hpo> (<z:chebi fb="0" ids="16990">bilirubin</z:chebi> &gt; or = 2 mg/dL), tender <z:hpo ids='HP_0002240'>hepatomegaly</z:hpo> and/or right upper quadrant pain, <z:hpo ids='HP_0001541'>ascites</z:hpo> and/or unexplained <z:mp ids='MP_0005456'>weight gain</z:mp> (&gt; 2% from baseline) </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients who were diagnosed with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e> received rt-PA (10-20 mg/day) and <z:chebi fb="5" ids="28304">heparin</z:chebi> (10,000 U/day) </plain></SENT>
<SENT sid="9" pm="."><plain>Three (37.5%) of the eight patients developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e> that occurred between 6 and 10 days posttransplant </plain></SENT>
<SENT sid="10" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> three patients developed <z:hpo ids='HP_0000952'>jaundice</z:hpo>, <z:mp ids='MP_0005456'>weight gain</z:mp>, and tender <z:hpo ids='HP_0002240'>hepatomegaly</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain><z:hpo ids='HP_0001541'>Ascites</z:hpo> and <z:hpo ids='HP_0000083'>renal insufficiency</z:hpo> occurred in two patients and <z:hpo ids='HP_0002202'>pleural effusion</z:hpo> in one patient </plain></SENT>
<SENT sid="12" pm="."><plain>rt-PA and <z:chebi fb="5" ids="28304">heparin</z:chebi> were begun 6 to 26 days posttransplant and rt-PA was administered for 7 to 14 days </plain></SENT>
<SENT sid="13" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> three patients responded to the therapy; <z:chebi fb="0" ids="16990">bilirubin</z:chebi> levels began to decrease at 4 to 13 days from the start of therapy </plain></SENT>
<SENT sid="14" pm="."><plain>They are <z:hpo ids='HP_0000001'>all</z:hpo> alive at day 111, 316, and 548 days posttransplant </plain></SENT>
<SENT sid="15" pm="."><plain>None of the patients had significant hemorrhagic complications after rt-PA treatment </plain></SENT>
<SENT sid="16" pm="."><plain>Prolonged administration of rt-PA was feasible without <z:mp ids='MP_0001914'>bleeding</z:mp> episode and it seems that rt-PA may alter the natural course of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e> </plain></SENT>
</text></document>